Evaluating PSA Density as a Predictor of Biochemical Failure after Radical Prostatectomy: Results of a Prospective Study after a Median Follow-Up of 36 Months

Table 2

Clinical and pathological characteristics of study cohort depending on the presence of biochemical recurrence.

	No recurrence	Recurrence	P
Number of patients, (%)	173 (70.9)	71 (29.1)
Age (years), mean ± std, IQR	66.3 ± 6.56, 9	65.9 ± 6.36, 11	0.527^†
PSA (ng/mL), mean ± std, IQR	8.37 ± 3.23, 4.29	9.99 ± 4.35, 5.20	0.005^†*
PSA density (ng/mL^2), mean ± std, IQR	0.29 ± 0.25, 0.18	0.46 ± 0.57, 0.27	0.002^†*
Preoperative Gleason score, n (%)			0.015^‡*
≤6	71 (41.0)	16 (22.5)
7	79 (45.7)	39 (54.9)
≥8	23 (13.3)	16 (22.5)
Pathological Gleason score, n (%)			0.423^‡
≤6	65 (37.6)	21 (29.6)
7	78 (45.1)	34 (47.9)
≥8	30 (17.3)	16 (22.5)
Clinical stage, n (%)			0.201^‡
T1c	134 (77.5)	47 (66.2)
T2a	29 (16.8)	16 (22.5)
T2b	8 (4.6)	8 (11.3)
T2c	2 (1.2)	0 (0)
Pathological stage, n (%)			0.001^‡*
T2a	19 (11.0)	6 (8.45)
T2b	7 (4.05)	1 (1.41)
T2c	104 (60.1)	38 (53.5)
T3a	36 (20.8)	11 (15.5)
T3b	7 (4.05)	15 (21.1)
Extracapsular disease, n (%)			0.064^‡
No	130 (75.1)	45 (63.4)
Yes	43 (24.9)	26 (36.6)
Surgical margins, n (%)			0.021^‡*
Negative	126 (72.8)	41 (57.7)
Positive	47 (27.2)	30 (42.3)
Seminal vesicles invasion, n (%)			<0.001^‡*
No	166 (96.0)	56 (78.9)
Yes	7 (4.05)	15 (21.1)
Lymph nodes invasion, n (%)			<0.001^‡*
No	83 (100.0)	39 (55.7)
Yes	0 (0)	31 (44.3)

†Mann-Whitney U test, ^‡chi-square test, *statistically significant, std: standard deviation, and IQR: interquartile range.